DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere Et Al US 2005O129775A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere et al. (43) Pub. Date: Jun. 16, 2005 (54) FERROMAGNETIC PARTICLES AND (22) Filed: Aug. 27, 2004 METHODS Related U.S. Application Data (75) Inventors: Janel Lanphere, Pawtucket, RI (US); Erin McKenna, Boston, MA (US); (63) Continuation-in-part of application No. 10/651,475, Thomas V. Casey II, Grafton, MA filed on Aug. 29, 2003. (US) Publication Classification Correspondence Address: FISH & RICHARDSON PC (51) Int. Cl." ........................... A61K 9/127; A61K 9/14; 225 FRANKLIN ST A61K 33/26 BOSTON, MA 02110 (US) (52) U.S. Cl. ............................................ 424/489; 424/646 (73) ASSignee: Siedle Systems, Inc., Maple (57) ABSTRACT (21) Appl. No.: 10/928,452 Ferromagnetic particles and methods are disclosed. Patent Application Publication Jun. 16, 2005 Sheet 1 of 5 US 2005/0129775 A1 Patent Application Publication Jun. 16, 2005 Sheet 2 of 5 US 2005/0129775 A1 s nS) l r N. 1 Yn ESDNIAJ?SdWßd N-EZT| 1 - - - - - - - - - - - - - - - - - - - - - - - - - a - - a - - - - Patent Application Publication Jun. 16, 2005 Sheet 3 of 5 US 2005/0129775 A1 : 3 L D Cl U c). Z Y X C) Patent Application Publication Jun. 16, 2005 Sheet 4 of 5 US 2005/0129775 A1 s s Patent Application Publication Jun. 16, 2005 Sheet 5 of 5 US 2005/0129775 A1 26SS EMBOLIC PARTICLES FIBROID jS. 111 UTERINE ARTERY CATHETER 150 FIG. R., US 2005/0129775 A1 Jun. 16, 2005 FERROMAGNETIC PARTICLES AND METHODS 0011 Heating a particle can include exposing the particle to RF radiation. CROSS-REFERENCE TO RELATED 0012. The particle can be disposed in a body lumen APPLICATIONS before being heated. Heating the particle heats body tissue 0001. This application is a continuation-in-part of, and adjacent the particle. claims priority under 35 U.S.C. S 120 to, U.S. patent appli 0013 The ferromagnetic material can include, for cation Ser. No. 10/651,475, entitled "Embolization,” and example, a transition metal, a metal alloy, and/or a metal filed on Aug. 29, 2003, which is incorporated herein by oxide. reference. 0014. The ferromagnetic material can be, for example, in TECHNICAL FIELD the shape of a particle, a fiber, a flake, and/or a powder. 0002 This invention relates to ferromagnetic particles 0015 The polymeric matrix (e.g., the gel polymeric and methods. matrix) can include, for example, a polyvinyl alcohol, a polyacrylic acid, a polymethacrylic acid, a poly Vinyl Sul BACKGROUND fonate, a carboxymethyl cellulose, a hydroxyethyl cellulose, a Substituted cellulose, a polyacrylamide, a polyethylene 0003) Therapeutic vascular occlusions (embolizations) glycol, a polyamide, a polyurea, a polyurethane, a polyester, are used to prevent or treat pathological conditions in situ. a polyether, a polystyrene, a polysaccharide (e.g. alginate), Compositions including embolic particles are used for a polylactic acid, a polyethylene, a polymethylmethacrylate, occluding vessels in a variety of medical applications. a polycaprolactone, a polyglycolic acid, and/or a poly(lactic Delivery of embolic particles through a catheter is depen co-glycolic) acid. dent on size uniformnity, density and compressibility of the embolic particles. 0016. In some embodiments, the density of the ferromag netic material in the interior region of the particle can be SUMMARY greater than a density of the ferromagnetic material at the Surface region of the particle. 0004. In one aspect, the invention features a method that includes providing a particle having a diameter of from 0017. In certain embodiments, there can be substantially about ten microns to about 3,000 microns. The particle no ferromagnetic material at the Surface region. includes a polymeric matrix, a ferromagnetic material and a 0018. In some embodiments, the particle can further therapeutic agent. The method also includes heating the include a therapeutic agent contained within the polymeric particle to release the therapeutic agent from the particle. matrix. 0005. In another aspect, the invention features a method 0019. In certain embodiments, the particle can further that includes disposing a particle in a body lumen. The include a coating Surrounding the polymeric matrix, the particle has a diameter of from about ten microns to about coating comprising a therapeutic agent. 3,000 microns, and the particle includes a polymeric matrix and a ferromagnetic material. The method also includes 0020. In some embodiments, the particle can further heating the particle to heat body tissue. include a third region between the interior region and the Surface region, the third region having a third density of 0006. In a further aspect, the invention features a particle pores less than the first density and less than the Second that includes a polymeric matrix and a ferromagnetic mate density. rial contained within the polymeric matrix. The particle has a first density of pores in an interior region and a Second 0021. In certain embodiments, a therapeutic agent can be density of pores at a Surface region. The first density being contained in the gel polymeric matrix. different from the second density. 0022. In some embodiments, the particle can further 0007. In an additional aspect, the invention features a include a coating Surrounding the gel polymeric matrix, the particle that includes a gel polymeric matrix and a ferro coating containing a therapeutic agent. magnetic material homogeneously distributed in the gel 0023 Embodiments of the invention may have one or polymer. more of the following advantages. 0008 Embodiments can include one or more of the 0024. In some embodiments, the positioning of the par following. ticle within a body lumen can be relatively easily and/or 0009. The particle can be heated, for example, to a non-invasively controlled using a magnetic field (e.g., a temperature of at least about 40 C. and/or a temperature of magnetic field outside a Subject, a magnetic field inside a at most about 200 C. Subject, or both). As an example, the particle can be steered through a body lumen (e.g., to a relatively distal location of 0010. In some embodiments, the method can include a lumen that might otherwise be difficult for the particle to providing a plurality of particles. Each of the particles can reach) by applying a magnetic field to the particle. AS have a diameter of from about ten microns to about 3,000 another example, the ability of the particle to migrate from microns, and each of the particles can include a polymeric a desired location can be reduced by applying a magnetic matrix, a ferromagnetic material and a therapeutic agent. field. The method can also include heating at least Some of the plurality of particles to release the therapeutic agent from the 0025. In certain embodiments, the particle can enhance particle. tissue heating and/or ablation procedures. For example, US 2005/0129775 A1 Jun. 16, 2005 when exposed to RF radiation, the particle can become 0037 AS used herein, a ferromagnetic material refers to heated and, in turn, heat the tissue. a material that has a magnetic Susceptibility of at least about 0.075 or more (e.g., at least about 0.1 or more; at least about 0.026 Features and advantages are in the description, 0.2 or more; at least about 0.3 or more; at least about 0.4 or drawings, and claims. more; at least about 0.5 or more; at least about one or more; at least about ten or more, at least about 100 or more, at least DESCRIPTION OF DRAWINGS about 1,000 or more; at least about 10,000 or more) when 0.027 FIG. 1 is a cross-sectional view of a particle. measured at 25 C. A ferromagnetic material can be, for example, a metal (e.g., a transition metal Such as nickel, 0028 FIG. 2 is a cross-sectional view of a particle. cobalt, or iron), a metal alloy (e.g., a nickel-iron alloy Such 0029 FIG. 3 is a cross-sectional view of a particle. as Mu-metal), a metal oxide (e.g., an iron oxide Such as magnetite), a ceramic nanomaterial, a Soft ferrite (e.g., 0030 FIG. 4 is a cross-sectional view of a particle. nickel–zinc-iron), a magnet alloy (e.g., a rare earth magnet 0.031 FIG. 5 is a cross-sectional view of a particle. alloy Such as a neodymium-iron-boron alloy or a Samarium cobalt alloy), an amorphous alloy (e.g., iron-Silicon-boron), 0.032 FIG. 6A is a schematic of an embodiment of a a non-earth alloy, or a silicon alloy (e.g., an iron-Zirconium system for manufacturing particles, and FIG. 6B is an copper-boron-Silicon alloy, an iron-Zirconium-copper-bo enlarged schematic of region 6B in FIG. 6A. ron-Silicon alloy). Magnetite is commercially available from 0.033 FIG. 7A is a schematic illustrating an embodiment FerroTec Corporation (Nashua, N.H.), under the tradename of injection of an embolic composition including embolic EMG 1111 Ferrofluid. Iron-copper-niobium-boron-silicon particles into a vessel, and FIG. 7B is an enlarged view of alloys are commercially available from Hitachi Metals of the region 7B in FIG. 7A. America under the tradename FinemetTM. Iron-zirconium copper-boron-Silicon alloys are commercially available DETAILED DESCRIPTION from MAGNETEC GmbH under the tradename Nanop ermE). In certain embodiments, the ferromagnetic material is 0034. The particle typically includes a polymeric matrix a biocompatible material (e.g., magnetite). In Some embodi (e.g., a gel polymeric matrix) and a ferromagnetic material. ments, the ferromagnetic material is a bioerodible material, 0035. The polymeric matrix can include one or more such that the material can eventually break down in the body polymer materials. Typically, the polymer material(s) is and either be dispersed throughout the body or excreted biocompatible.
Load more

Recommended publications
  • Supplement 12
    APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 14TH EDITION Cumulative Supplement 1 2 DECEMBER 1994 CONTENTS PAGE 1.0 INTRODUCTION............................................. iii 1.1 Ilow to Use the Cumulative Supplement .. iii 1.2 Products Requiring Revised Labeling for Full Approval . v 1.3 Applicant Name Changes. vi 1.4 New Indications for Previously Approved Drug Products ............... vii 1 .5 USP Monograph Title Additions or Changes . ix 1.6 Report of Counts for the Prescription Drug Product List. x 2.0 DRUG PRODUCT LISTS ....................................... 2.1 Prescription Drug Product List ................................. 1 2.2 OTC Drug Product List ...................................... 61 2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List. 63 2.4 Orphan Drug Product Designations . 64 2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution ................ 70 2.6 Biopharmaceutic Guidance Availability ........................... 71 2.7 ANDA Suitability Petitions . 72 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM A. Exclusivity Terms. 74 B. Patent and Exclusivity Lists . 76 APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 14TH EDITION CUMULATIVE SUPPLEMENT 12 DECEMBER 1994 1.0 INTRODUCTION 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence
    [Show full text]
  • LGC Standards Pharmacopoeial Reference Standards 2014
    LL CTS INKSP RODUTO A L P ITH W WEBSHO LGC Standards Pharmacopoeial reference standards 2014 FOR STANDARDS WITH CofA SEE OUR CATALOGUE: PHARMACEUTICAL IMPURITIES AND PRIMARY REFERENCE STANDARDS LGC Quality – ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Pharmaceutical impurities Code Product CAS No. CS Price Unit Adiphenine Hydrochloride O LGC Standards N O MM1172.00 Adiphenine Hydrochloride 50-42-0 A 250mg HCl Pharmaceutical impurities and Adrenaline Tartrate OH H OH O OH primary reference standardsMM0614.00 2014 N OH Adrenaline Tartrate 51-42-3 A 500mg OH OH O OH OH H MM0614.02 L-Adrenaline 51-43-4 A 500mg OH N OH Imp. C (EP) as Hydrochloride: 1-(3,4-Di- O H OH MM0614.13 hydroxyphenyl)-2-(methylamino)ethanone 62-13-5 A 100mg N HCl Hydrochloride (Adrenalone Hydrochloride) OH (1R)-1-(3,4-Dihydroxyphenyl)-2- OH O S O MM0614.01 methylaminoethanesulphonic Acid H 78995-75-2 A 100mg OH N (Adrenaline -Sulphonate) OH Alanine NH2 MM0566.00 Alanine 56-41-7 A 500mg OH O Imp. A (Pharmeuropa): (2 S)-2-Aminobutanedioic Acid O NH 2 MM0567.00 OH (Aspartic Acid) 56-84-8 A 500mg OH O Albendazole O H MM0382.00 Albendazole N O 54965-21-8 A 500mg N H S N Imp. A (EP): 5-(Propylsulphanyl)-1H- H MM0382.01 N 80983-36-4 A 100mg NH2 benzimidazol-2-amine S N O H Imp. B (EP): Methyl [5-Propylsulphinyl)- N O MM0382.02 N 54029-12-8 A 100mg H 1H-benzimidazol-2-yl]carbamate S N O O H Imp.
    [Show full text]
  • Iodine-Containing Drugs
    Iodine-containing drugs Iodine-containing drugs (iodine) usually have an iodine content of >5mg/tablet or ml. The antiarrhythmic agent amiodarone, for example, contains 75 mg iodine/tablet, 10 ml betaisodona solution about 110 mg . - The administration of X-ray contrast media is another important reason for excessive iodine exposure. X-ray contrast media frequently contain > 100 mg iodine/ml. Contrast media contain almost exclusively organically bound iodine, but in vivo these compounds are partially deiodinated (deiodinase) (Mann et al. Eur J. Endocrinol 1994; 130 (5): 498). Assuming that water-soluble contrast media is eliminated within 10 to 14 days, enzymatic separation of iodine nevertheless leads to an offer of about 14 to 175 mg in the thyroid. Fat-soluble contrast media applied in cholecystograms have a much longer half time in the organism, and iodine can consequently be separated long. The table of Surks et al. (New Engl J Med 1995; 333: 1688) gives a survey of the most important iodine preparations applied in the USA. Iodine Content of Some Iodine Containing Medications and Radiographic Contrast Agents SUBSTANCE AMOUNT OF IODINE Expectorants Iophen 25 mg/ml Organidin (iodinated glycerol) 15 mg/tablet Par Glycerol 5 mg/ml R-Gen 6 mg/ml Iodides Potassium iodide (saturated solution) -25 mg/drop Pima syrup (potassium iodide) 255 mg/ml Lugol's solution (potassium iodide -7 mg/drop + iodine) Iodo-Niacin 115 mg/tablet Antiasthmatic drugs Mudrane 195 mg/tablet Elixophyllin-KI (theophylline) elixir 6.6 mg/ml © Merck KGaA 2002 Iophylline 2 mg/ml Antiarrhythmic drugs Amiodarone 75 mg/tablet Antiamebic drugs Iodoquinol 134 mg/tablet Topical antiseptic agents Poidone-iodine 10 mg/ml Clioquinol 12 mg/g Douches Povidone-iodine 10 mg/ml Radiographic contrast agents Iopanoic acid 333 mg/tablet Ipodate sodium 308 mg/tablet Intravenous preparations 140-380 mg/ml M.J.
    [Show full text]
  • Summary and Recommendations for Thyroid Screening in Pregnancy: Is
    Gregory A. Brent, MD Departments of Medicine and Physiology David Geffen School of Medicine at UCLA Etiologies of Hypothyroidism • Chronic autoimmune thyroiditis-Hashimoto’s disease • Partial thyroidectomy. • Radioactive iodine therapy for treatment of hyperthyroidism. • External radiotherapy of the head and neck in patients with Hodgkin’s lymphoma, leukemia, brain tumors, or bone-marrow transplantation. • Infiltrative disorders of the thyroid gland (eg, amyloidosis, sarcoidosis,hemochromatosis, or Riedel’s thyroiditis). Modified from Cooper and Biondi Lancet 379:1142, 2012 Pearce and Braverman Best Pract Clin Endo Metab 23:801, 2009 Agent Example of Sources Mode of Action Thyroid Disease in Humans Polychlorinated Found in coolants and TR Possible increase in biphenyls (PCBs) lubricants, properties; agonist/antagonist, TSH, thyroid multiple congeners, can alter levels of T4 autoantibodies, thyroid lipophilic and TSH volume Organochlorine Used as pesticide on Induce hepatic No established pesticides crops glucuronyltransferase association (UDPGTs) Polybrominated Found in flame Bind to TRs, Increase in diphenylethers retardants displaces T4 from hypothyroidism in some (PBDEs) binding proteins studies Bisphenol-A (BPA) Used in plastic bottles Antagonize TR, lower No established serum T4 association Adapted from Brent GA Thyroid 20:755, 2010 Agent Example of Mode of Action Thyroid Disease Sources In Humans Perchlorate, Rocket fuel, Inhibits iodine No established Thiocyanate fertilizer, uptake, at sufficient association smoking levels reduces
    [Show full text]
  • PF 41(4) Table of Contents Publish Date: Jul 1, 2015
    PF 41(4) Table of Contents Publish date: Jul 1, 2015 PROPOSED IRA Proposed IRA Intro Section USP MONOGRAPHS Methocarbamol (1-Jan-2016) Protamine Sulfate Injection (1-Jan-2016) IN-PROCESS REVISION IPR Introduction GENERAL CHAPTERS <1130> NUCLEIC ACID-BASED TECHNIQUES—APPROACHES FOR DETECTING TRACE NUCLEIC ACIDS (RESIDUAL DNA TESTING) (USP39-NF34 2S) REAGENTS, INDICATORS, AND SOLUTIONS Reagent Specifications Carbon Tetrachloride (USP39-NF34 2S) 4-Hydroxy-4-phenylpiperidine [NEW] (USP39-NF34 2S) Monosodium Glutamate [NEW] (USP39-NF34 2S) 6Z-Retinoic Acid [NEW] (USP39-NF34 2S) Sulfaguanidine [NEW] (USP39-NF34 2S) Chromatographic Columns L## (Tretinoin, Cosmosil Cholesterol) [NEW] (USP39-NF34 2S) REFERENCE TABLES Container Specifications Containers for Dispensing Capsules and Tablets [NEW] (USP39-NF34 2S) Description and Solubility Description and Solubility of USP and NF Articles [NEW] (USP39-NF34 2S) Description and Solubility - C Description and Solubility - F Description and Solubility - M DIETARY SUPPLEMENT MONOGRAPHS Methylcobalamin Tablets [NEW] (USP39-NF34 2S) Northern Schisandra Fruit Dry Extract [NEW] (USP39-NF34 2S) PF 41(4) Table of Contents 1 | Page NF MONOGRAPHS Chlorobutanol (USP39-NF34 2S) Eucalyptus Oil (USP39-NF34 2S) USP MONOGRAPHS Albuterol Sulfate (USP39-NF34 2S) Alprazolam Extended-Release Tablets (USP39-NF34 2S) Alprazolam Orally Disintegrating Tablets (USP39-NF34 2S) Aminobenzoate Potassium (USP39-NF34 2S) Aminobenzoate Potassium Capsules (USP39-NF34 2S) Aminobenzoate Sodium (USP39-NF34 2S) Gamma-Aminobutyric Acid Capsules
    [Show full text]
  • Col11bined Index to USP 37 and NF 32, Volul11es 1-4
    ..... Combined Index to USP 37 and NF 32 Abaca-Aceto 1-1 COl11bined Index to USP 37 and NF 32, Volul11es 1-4 Page citations refer to the pages of Volumes 7, 2, 3, and 4 of uSP 37-NF 32. This index is repeated in its entirety in each volume. 1-1554 Volume 1 1555-3460 Volume 2 3461-5230 Volume 3 5231-6262 Volume 4 Numbers in angle brackets such as (421) refer to chapter numbers in the General Chapters section. and (salts of) chlorpheniramine, isometheptene mucate, and dextromethorphan, and dichloralphenazone capsules, 3416 phenylpropanolamine, oral solution and oxycodone capsules, 4141 Abacavir containing at least three of the and oxycodone tablets, 4142 oral solution, 1S5 5 following, 1576 and pentazocine tablets, 4231 sulfate, 1556 and (salts of) chlorpheniramine, and propoxyphene hydrochloride tablets, tablets, 1557 dextromethorphan, and 4458 Absolute phenylpropanolamine, tablets containing and propoxyphene napsylate tablets, 4463 alcohol, 1373 at least three of the following, 1577 and pseudoephedrine hydrochloride ether, 1372 and (salts of) chlorpheniramine, tablets, 1597 Absorbable dextromethorphan, and oral solution, 1566 dusting powder, 2745 pseudoephedrine, capsules containing at for effervescent oral solution, 1567 gelatin film, 3132 least three of the following, 1579 suppositories, 1567 gelatin sponge, 3132 and (salts of) chlorpheniramine, oral suspension, 1568 surgical suture, 4808 dextromethorphan, and tablets, 1569 Absorbent pseudoephedrine, oral powder extended-release tablets, 1570 cotton, 1372 containing at least three of
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0051758 A1 Rioux Et Al
    US 20080051758A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0051758 A1 Rioux et al. (43) Pub. Date: Feb. 28, 2008 (54) MEDICAL DEVICES (21) Appl. No.: 11/458,171 (75) Inventors: Robert F. Rioux, Ashland, MA (22) Filed: Jul. 18, 2006 (US); David J. Sauvageau, Methuen, MA (US) Publication Classification Correspondence Address: ( 51) Int. Cl. FSH & RICHARDSON PC A6M 3L/00 (2006.01) P.O. BOX 1022 (52) U.S. Cl. ....................................................... 6O4/509 MINNEAPOLIS, MN 55440-1022 (57) ABSTRACT (73) Assignee: BOSTON SCIENTIFIC SCIMED, INC., Maple Grove, Medical devices, and related components and methods, are MN (US) disclosed. Patent Application Publication Feb. 28, 2008 Sheet 1 of 10 US 2008/0051758A1 - Ya-a-a- ..……*** - *****-----.…... k *********~~~~….…***** ...º.………·~~~~-….….---******* ...…--~~~~*~~~~ -…--~~~” Patent Application Publication Feb. 28, 2008 Sheet 2 of 10 US 2008/0051758A1 Patent Application Publication Feb. 28, 2008 Sheet 3 of 10 US 2008/0051758A1 Patent Application Publication US 2008/0051758A1 Patent Application Publication Feb. 28, 2008 Sheet 5 of 10 US 2008/0051758A1 F. G. 2D Patent Application Publication Feb. 28, 2008 Sheet 6 of 10 US 2008/0051758A1 FG. 3B Patent Application Publication Feb. 28, 2008 Sheet 7 of 10 US 2008/0051758A1 **********************~~~~~~~~========.=…-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.- ·****************************. o,,,~~~ Patent Application Publication Feb. 28, 2008 Sheet 8 of 10 US 2008/0051758A1 G. 5B Patent Application Publication Feb. 28, 2008 Sheet 9 of 10 US 2008/0051758A1 F.G. 5C Patent Application Publication Feb. 28, 2008 Sheet 10 of 10 US 2008/0051758A1 US 2008/0051758 A1 Feb. 28, 2008 MEDICAL DEVICES the lumen of the generally tubular member, and/or at least one contrast agent can be flowed through the lumen of the TECHNICAL FIELD generally tubular member.
    [Show full text]
  • 1484 Contrast Media
    1484 Contrast Media myelography, see under Iohexol, p.1483; for specific references, to iodine or to other contrast media, severe hyperthyroidism, hy- Profile see below. peruricaemia, or cholangitis. Because of its cholinergic action, Iopentol is a nonionic monomeric iodinated radiographic con- Effects on the nervous system. Reports of serious neurolog- premedication with atropine has been suggested in some coun- trast medium (see p.1474). It may be given intravenously, intra- ical sequelae to lumbar myelography with iopamidol. tries for patients with coronary heart disease. Iodine-containing arterially, orally, or by instillation into body cavities, and is used contrast media may interfere with thyroid-function tests and with in procedures including angiography, arthrography, endoscopic 1. Wallers K, et al. Severe meningeal irritation after intrathecal in- jection of iopamidol. BMJ 1985; 291: 1688. some blood and urine tests. retrograde cholangiopancreatography, hysterosalpingography, urography, and visualisation of the gastrointestinal tract. It is also 2. Robinson C, Fon G. Adverse reaction to iopamidol. Med J Aust Breast feeding. No adverse effects have been observed in 1986; 144: 553. used for contrast enhancement in computed tomography. breast-feeding infants whose mothers were receiving iopanoic 3. Bell JA, McIlwaine GG. Postmyelographic lateral rectus palsy 1 associated with iopamidol. BMJ 1990; 300: 1343–4. acid and the American Academy of Pediatrics considers that it Iopentol is usually available as solutions containing 32.9 to 4. Mallat Z, et al. Aseptic meningoencephalitis after iopamidol my- is therefore usually compatible with breast feeding. 76.8% of iopentol (equivalent to 150 to 350 mg/mL of iodine) elography. Lancet 1991; 338: 252.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al
    US 2002001 0208A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua et al. (43) Pub. Date: Jan. 24, 2002 (54) DHA-PHARMACEUTICAL AGENT Related U.S. Application Data CONJUGATES OF TAXANES (63) Continuation of application No. 09/135,291, filed on (76) Inventors: Victor Shashoua, Brookline, MA (US); Aug. 17, 1998, now abandoned, which is a continu Charles Swindell, Merion, PA (US); ation of application No. 08/651,312, filed on May 22, Nigel Webb, Bryn Mawr, PA (US); 1996, now Pat. No. 5,795,909. Matthews Bradley, Layton, PA (US) Publication Classification Correspondence Address: Edward R. Gates, Esq. (51) Int. Cl." ............................................ A61K 31/337 Wolf, Greenfield & Sacks, P.C. (52) U.S. Cl. .............................................................. 514/449 600 Atlantic Avenue Boston, MA 02210 (US) (57) ABSTRACT The invention provides conjugates of cis-docosahexaenoic (21) Appl. No.: 09/846,838 acid and pharmaceutical agents useful in treating noncentral nervous System conditions. Methods for Selectively target 22) Filled: Mayy 1, 2001 ingg pharmaceuticalp agents9. to desired tissues are pprovided. Patent Application Publication Jan. 24, 2002 Sheet 1 of 14 US 2002/0010208A1 1 OO 5 O -5OO - 1 OO-9 -8 -7 -6 -5 -4 LOG-10 OF SAMPLE CONCENTRATION (MOLAR) CCRF-CEM-o- SR ----- RPM-8226----- K-562- - -A - - HL-60 (TB) -g- - MOLT4: ... O Fig. 1 1 OO 5 O -5OO -1 O O -8 -7 -6 -5 -4 -- 9 LOGo OF SAMPLE CONCENTRATION (MOLAR) A549/ATCC-o-NS326. NCEKVX 28. --Q-- NCI-H322M-...-a---Eidsf8::... NC-H522--O-- HOP-62---Fig. 2 a-- NC-H460.-------- Patent Application Publication Jan.
    [Show full text]
  • DRUG-INDUCED HYPOTHYROIDISM Drug-Induced Primary
    394 MEDICINA - VolumenISSN 77 - Nº1669-9106 5, 2017 SPECIAL ARTICLE MEDICINA (Buenos Aires) 2017; 77: 394-404 DRUG-INDUCED HYPOTHYROIDISM LEONARDO F. L. RIZZO1, DANIELA L. MANA1, HÉCTOR A. SERRA1, 2 1Dirección Médica Química Montpellier SA, 2Cátedra de Farmacología, Facultad de Ciencias Médicas, U.C.A., Buenos Aires, Argentina Abstract The thyroid axis is particularly prone to interactions with a wide variety of drugs, whose list increases year by year. Hypothyroidism is the most frequent consequence of drug-induced thyroid dysfunction. The main mechanisms involved in the development of primary hypothyroidism are: inhibition of the synthesis and/ or release of thyroid hormones, immune mechanisms related to the use of interferon and other cytokines, and the induction of thyroiditis associated with the use of tyrosine kinase inhibitors and drugs blocking the receptors for vascular endothelial growth factor. Central hypothyroidism may be induced by inhibition of thyroid-stimulating hormone (bexarotene or corticosteroids) or by immunological mechanisms (anti-CTLA4 or anti-PD-1 antibody drugs). It is also important to recognize those drugs that generate hypothyroidism by interaction in its treatment, either by reducing the absorption or by altering the transport and metabolism of levothyroxine. Thus, it is strongly recommended to evaluate thyroid function prior to the prescription of medications such as amiodarone, lithium, or interferon, and the new biological therapies that show important interaction with thyroid and endocrine function in general. Key words: thyroid, hypothyroidism, drugs Resumen Hipotiroidismo inducido por drogas. El eje tiroideo es particularmente proclive a sufrir interacciones con una amplia variedad de drogas, cuya lista se acrecienta año a año.
    [Show full text]
  • Revised References to Heavy Metals <231>
    Revised References to Heavy Metals <231> Targeted Official Date for Omission of References: 01-January-2018 Title File Type <3> Topical And Transdermal Drug Products--Product Quality Tests General Chapter <661> Containers--Plastics General Chapter <1059> Excipient Performance General Chapter <1086> Impurities In Drug Substances And Drug Products General Chapter <1151> Pharmaceutical Dosage Forms USP Acarbose USP Acebutolol Hydrochloride USP Acesulfame Potassium NF Acetaminophen USP Acetazolamide USP Acetic Acid NF Diluted Acetic Acid NF Glacial Acetic Acid USP & NF Acetohexamide USP Acetohydroxamic Acid USP Acetylcysteine USP & NF Acetyltributyl Citrate NF Acetyltriethyl Citrate NF Acetyltyrosine DS Acitretin USP Adapalene USP Adenine USP Adenosine USP S-Adenosyl-L-methionine Disulfate Tosylate DS Adipic Acid NF Agar NF Alanine USP & DS Alclometasone Dipropionate USP Alcohol in Dextrose Injection USP Alendronate Sodium USP Alfadex NF Alginic Acid NF Alprazolam USP Altretamine USP Ammonium Alum USP Potassium Alum USP Alumina and Magnesia Oral Suspension USP Alumina, Magnesia, and Calcium Carbonate Oral Suspension USP Aluminum Acetate Topical Solution USP Aluminum Chloride USP Aluminum Chlorohydrate USP Aluminum Chlorohydrate Solution USP Aluminum Chlorohydrex Polyethylene Glycol USP Aluminum Chlorohydrex Propylene Glycol USP Aluminum Dichlorohydrate USP Aluminum Dichlorohydrate Solution USP Aluminum Dichlorohydrex Polyethylene Glycol USP Aluminum Dichlorohydrex Propylene Glycol USP Aluminum Hydroxide Gel USP Dried Aluminum Hydroxide Gel
    [Show full text]
  • Supplement 12
    '95 15TH EDITION U.S DEPARTMENT OF HEALTH AND HUMAN$iER\WIC;ES PUBUC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION ANDHESEAlRCH OFFICE OF MANAGEMENT . IJIVISION OF DRUG INFORMATION RESOURCES SUBSCRIBE NOW! Available in March 1996 New 16th Edition APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 16lli EDITION 1996 CONTENTS • Prescription Drug Product List .' • OTC Drug Product List • Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List • Discontinued Drug Product List • USP Monograph Title Additions or Changes • Orphan Drug Product Designations • Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution • Biopharmaceutic Guidance Availability • ANDA Suitability Petitions • Patent and Exclusivity Information See Subscription Form Inside Back Cover APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 15TH EDITION Cumulative Supplement 12 DECEMBER 1995 CONTENTS PAGE 1.0 INTRODUCTION.............................................. iii 1 .1 How to Use the Cumulative Supplement ........................... iii 1.2 Court Order Affecting Uruguay Round Agreements Act-Extended Patents .... iv 1.3 Products Requiring Revised Labeling for Full Approval . v 1.4 Applicant Name Changes . vi 1.5 Availability of the Publication and Updating Procedures . vii 1.6 Report of Counts for the Prescription Drug Product List. viii 2.0 DRUG PRODUCT LISTS ........................................ 2.1 Prescription Drug Product List ................................. 2.2 OTC Drug Product List ...................................... 68 2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List ..... 73 2.4 Orphan Drug Product Designations .............................. 74 2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution ...............
    [Show full text]